Research ExplorerPublications111In-octreotide imaging in patients with long-standing Grav...

111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.

Standard

111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy. / Bohuslavizki, K H; Oberwöhrmann, S; Brenner, Winfried; Eberhardt, J U; Mönig, H; Clausen, M; Sippel, C; Wolf, H; Epe, B; Henze, E.

In: NUCL MED COMMUN, Vol. 16, No. 11, 11, 1995, p. 912-916.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bohuslavizki, KH, Oberwöhrmann, S, Brenner, W, Eberhardt, JU, Mönig, H, Clausen, M, Sippel, C, Wolf, H, Epe, B & Henze, E 1995, '111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.', NUCL MED COMMUN, vol. 16, no. 11, 11, pp. 912-916. <http://www.ncbi.nlm.nih.gov/pubmed/8587756?dopt=Citation>

APA

Bohuslavizki, K. H., Oberwöhrmann, S., Brenner, W., Eberhardt, J. U., Mönig, H., Clausen, M., Sippel, C., Wolf, H., Epe, B., & Henze, E. (1995). 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy. NUCL MED COMMUN, 16(11), 912-916. [11]. http://www.ncbi.nlm.nih.gov/pubmed/8587756?dopt=Citation

Vancouver

Bohuslavizki KH, Oberwöhrmann S, Brenner W, Eberhardt JU, Mönig H, Clausen M et al. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy. NUCL MED COMMUN. 1995;16(11):912-916. 11.

Bibtex

@article{4212f275c82e426fb50b09d739aed7cd,
title = "111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.",
abstract = "The aim of this study was to examine patients with long-standing Graves' ophthalmopathy using 111In-octreotide scintigraphy. Sixteen patients with inactive ophthalmopathy of up to 114 months duration and 14 normals were investigated for 48 h following an injection of 200 MBq 111In-octreotide. No significant tracer accumulation in the orbital region could be identified in any of the patients with long-standing Graves' ophthalmopathy. The orbit to brain (O/B) ratios after 24 and 48 h were 2.39 +/- 0.36 and 2.15 +/- 0.44 versus 2.17 +/- 0.33 and 2.20 +/- 0.37 for the patients and normals, respectively (N.S.). 111In-octreotide accumulation in ophthalmopathy described in the literature may thus be a passing event limited to its active stage, which is consistent with the concept of imaging a lymphocytic infiltration. In this study, the lack of accumulation of 111In-octreotide in the orbital region during the inactive stage demonstrates an absence of somatostatin receptors in orbital tissue itself. Thus, in patients with inactive Graves' ophthalmopathy, there is no basis for a diagnostic approach with somatostatin.",
author = "Bohuslavizki, {K H} and S Oberw{\"o}hrmann and Winfried Brenner and Eberhardt, {J U} and H M{\"o}nig and M Clausen and C Sippel and H Wolf and B Epe and E Henze",
year = "1995",
language = "Deutsch",
volume = "16",
pages = "912--916",
journal = "NUCL MED COMMUN",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

RIS

TY - JOUR

T1 - 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.

AU - Bohuslavizki, K H

AU - Oberwöhrmann, S

AU - Brenner, Winfried

AU - Eberhardt, J U

AU - Mönig, H

AU - Clausen, M

AU - Sippel, C

AU - Wolf, H

AU - Epe, B

AU - Henze, E

PY - 1995

Y1 - 1995

N2 - The aim of this study was to examine patients with long-standing Graves' ophthalmopathy using 111In-octreotide scintigraphy. Sixteen patients with inactive ophthalmopathy of up to 114 months duration and 14 normals were investigated for 48 h following an injection of 200 MBq 111In-octreotide. No significant tracer accumulation in the orbital region could be identified in any of the patients with long-standing Graves' ophthalmopathy. The orbit to brain (O/B) ratios after 24 and 48 h were 2.39 +/- 0.36 and 2.15 +/- 0.44 versus 2.17 +/- 0.33 and 2.20 +/- 0.37 for the patients and normals, respectively (N.S.). 111In-octreotide accumulation in ophthalmopathy described in the literature may thus be a passing event limited to its active stage, which is consistent with the concept of imaging a lymphocytic infiltration. In this study, the lack of accumulation of 111In-octreotide in the orbital region during the inactive stage demonstrates an absence of somatostatin receptors in orbital tissue itself. Thus, in patients with inactive Graves' ophthalmopathy, there is no basis for a diagnostic approach with somatostatin.

AB - The aim of this study was to examine patients with long-standing Graves' ophthalmopathy using 111In-octreotide scintigraphy. Sixteen patients with inactive ophthalmopathy of up to 114 months duration and 14 normals were investigated for 48 h following an injection of 200 MBq 111In-octreotide. No significant tracer accumulation in the orbital region could be identified in any of the patients with long-standing Graves' ophthalmopathy. The orbit to brain (O/B) ratios after 24 and 48 h were 2.39 +/- 0.36 and 2.15 +/- 0.44 versus 2.17 +/- 0.33 and 2.20 +/- 0.37 for the patients and normals, respectively (N.S.). 111In-octreotide accumulation in ophthalmopathy described in the literature may thus be a passing event limited to its active stage, which is consistent with the concept of imaging a lymphocytic infiltration. In this study, the lack of accumulation of 111In-octreotide in the orbital region during the inactive stage demonstrates an absence of somatostatin receptors in orbital tissue itself. Thus, in patients with inactive Graves' ophthalmopathy, there is no basis for a diagnostic approach with somatostatin.

M3 - SCORING: Zeitschriftenaufsatz

VL - 16

SP - 912

EP - 916

JO - NUCL MED COMMUN

JF - NUCL MED COMMUN

SN - 0143-3636

IS - 11

M1 - 11

ER -